Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Use of second antibody in radioimmunotherapy

Journal Article · · NCI Monogr.; (United States)
OSTI ID:6518729
In this study, a second antibody was directed against the first antitumor antibody to accelerate clearance of the /sup 131/I-labeled first antibody and improve tumor to normal tissue ratios of radioactivity. The value of this method in improving the therapeutic index of radioimmunotherapy with /sup 131/I-antibody to CEA has been investigated in nude mice bearing xenografts of human colon carcinoma and in 5 patients with colorectal cancer. The xenografts did not become saturated with anti-CEA as the administered dose was increased to therapeutic levels. At these high dose levels, the second antibody increased tumor to blood ratios to a maximum of 155:1, 48 times the level in controls that did not receive the second antibody. In 5 patients given 50 mCi of anti-CEA, there was no significant toxicity with the second antibody; clearance of radioactivity was accelerated; and tumor imaging was enhanced. The second antibody appears to have the potential to improve the therapeutic index of radioimmunotherapy.
Research Organization:
Charing Cross and Westminster Medical School, London, England
OSTI ID:
6518729
Journal Information:
NCI Monogr.; (United States), Journal Name: NCI Monogr.; (United States) Vol. 3; ISSN NCIME
Country of Publication:
United States
Language:
English